Form 4: Lyell Immunopharma Director Cathy Friedman Reports Acquisition of Stock Options

Director Cathy Friedman reports the acquisition of 130,000 stock options in Lyell Immunopharma, Inc.

Summary

• Cathy Friedman, a director of Lyell Immunopharma, Inc., filed a Form 4 on June 17, 2024, reporting changes in beneficial ownership.
• The earliest transaction date was June 14, 2024.
• Friedman acquired 130,000 options to buy common stock at an exercise price of $2.36.
• These options vest on the earlier of the next annual meeting following June 14, 2024, or the first anniversary of that date, contingent on continuous service.
• Friedman also indirectly owns 236,370 shares of common stock through the Duane Family Trust and 100,000 shares through The Duane Irrevocable Trust 2020, for which she serves as a trustee.
• Friedman disclaims beneficial ownership of shares held by these trusts except to any pecuniary interest therein.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. The acquisition of options could be seen as a slightly positive indicator of the director's confidence in the company.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on continued service, suggesting an expectation of ongoing involvement.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to align the interests of their leadership with those of shareholders.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director can have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates